查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
疫苗佐劑市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按佐劑類別、類型和地理位置
市場調查報告書
商品編碼
1424131

疫苗佐劑市場規模和預測、全球和地區佔有率、趨勢和成長機會分析報告範圍：按佐劑類別、類型和地理位置

Vaccine Adjuvant Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Adjuvant Class, Type, and Geography
出版日期: | 出版商: The Insight Partners | 英文 155 Pages | 訂單完成後即時交付

價格

疫苗佐劑市場預計將從2022年的24.82億美元成長到2028年的69.31億美元；預計 2022 年至 2028 年CAGR為13.7%。對佐劑研究發展的支持和產品發布的合作努力為疫苗佐劑市場創造了機會，這是推動疫苗佐劑市場成長的有影響力的市場成長的獨立因素。

佐劑是添加到疫苗製劑中的成分，可以使接受疫苗的人產生更強的免疫反應。傳染病爆發和大流行的增加以及獸用疫苗佐劑的監管批准是推動市場發展的關鍵因素。然而，產品召回和不良影響阻礙了疫苗佐劑市場的成長。

成長動力：

支持佐劑研究的發展和產品上市的合作努力為疫苗佐劑市場創造機會

美國國家過敏和傳染病研究所 (NIAID) 在開發、發現和表徵新型疫苗佐劑方面發揮重要作用。該研究所在提高現有疫苗的功效、針對現有和新出現的傳染病設計新的或更好的疫苗以及開發治療過敏、自體免疫疾病和癌症的疫苗方面發揮著至關重要的作用。此外，NIAID的疫苗佐劑研究計畫旨在開發一套佐劑，包括可以與抗原匹配以最佳化最終疫苗功效的候選劑。因此，為了促進NIAID 支持的疫苗佐劑研究人員與更廣泛的科學界之間的合作，NIAID 於2020 年建立了疫苗佐劑綱要(VAC)。這個基於網路的工具顯示佐劑特徵，以幫助疫苗開發人員識別適合其目標疾病的佐劑。

SK Biosciences 和 GSK 等疫苗業務公司正在透過實施合作等成長策略來大規模生產佐劑，以滿足全球需求。例如，2022 年 4 月，SK Biosciences 和 GSK 在 3 期臨床試驗獲得積極資料後宣布向韓國食品藥物安全部 (KMFDS) 提交 SKYCovione 的生物許可申請。因此，各政府部門為促進疫苗佐劑研發提供的支援、頂級製造商之間的合作以及透過此類合作業務策略推出創新產品可能會在預測期內為疫苗佐劑市場的成長提供利潤豐厚的機會。

按佐劑類別，礦物鹽佐劑細分市場在 2022 年佔據疫苗佐劑市場的最大佔有率。乳劑佐劑細分市場預計在預測期內將以 14.6% 的最快CAGR成長。礦物鹽如不溶性鋁鹽和磷酸鈣在疫苗製劑中用作佐劑。鋁鹽佐劑有助於誘導早期和持久的保護性免疫力。用於人類疫苗的鋁佐劑受到美國食品藥物管理局 (FDA) 的監管，添加少量的鋁可以幫助人體建立比疫苗中單獨抗原更高的免疫原性。發炎部位的礦物鹽佐劑配方透過釋放促發炎細胞激素產生快速免疫反應。因此，礦物鹽佐劑誘導針對抗原的快速免疫反應的能力有利於疫苗佐劑市場的成長。

2022年，北美貢獻了全球最大的疫苗佐劑市場。預計亞太地區 2022 年至 2030 年CAGR最高。疫苗佐劑產品核准的加速促進了北美市場的成長。此外，生產助劑的頂級製造商的存在進一步促進了整體市場的成長。

快速的產品核准流程有利於美國的疫苗佐劑市場。 2023年5月，葛蘭素史克（GSK）的Arexvy（呼吸道合胞病毒疫苗，佐劑）獲得美國食品藥物管理局（FDA）批准，旨在預防呼吸道合胞病毒（RSV）引起的下呼吸道疾病（LRTD） 。因此，Arexvy 成為世界上第一個 FDA 批准的針對老年人的 RSV 疫苗。 2022 年 10 月，Novavax, Inc. 的 COVID-19 佐劑疫苗獲得 FDA 的緊急使用授權 (EUA)，該疫苗可作為成年患者的加強疫苗。

產業發展及未來機會：

以下列出了疫苗佐劑市場領導企業的各種策略發展：

2022 年 4 月，GSK plc 和 SK Bioscience 提交了 SKYCovione 的生物製品許可申請，​​SKYCovione 是一種基於重組蛋白的佐劑 COVID-19 候選疫苗。它含有葛蘭素史克的大流行佐劑。在 III 期臨床試驗獲得積極資料後，這些公司已向韓國食品藥品安全部提交了生物製品許可申請。

2021年11月，Seppic推出了MONTANIDE GEL P PR，這是一種基於聚合物技術的水性佐劑，專門用於禽類注射疫苗，滿足禽類市場對無害性的需求。此外，MONTANIDE GEL P PR 特別穩定，可抵抗禽類疫苗中常用的不穩定抗原介質。

2023 年10 月，SPI Pharma Inc. 和Q-Vant Biosciences Inc. 宣佈建立合作夥伴關係，將Q-Vant 在永續皂苷萃取技術方面的領先地位與SPI 在製藥業的全球影響力和服務專業知識結合起來。該安排包括投資擴大 Q-Vant 專有的 100% 永續 Q-SAP 技術，以及一項獨家商業協議，以加速其皂苷佐劑在獸醫和人類疫苗配方中的全球採用。

2023 年 1 月，韓國食品藥物安全部 (KMFDS) 授予 SK Bioscience NuvaxovidTM 增強型生產和行銷授權，作為加強劑給 18 歲及以上的成年人服用。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 重要見解

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：疫苗佐劑市場格局

  • PEST分析

第 5 章：疫苗佐劑市場 - 主要市場動態

  • 疫苗佐劑市場 - 主要市場動態
  • 市場促進因素
    • 傳染病爆發和大流行的數量不斷增加
    • 獸用疫苗佐劑的核准
  • 市場限制
    • 產品召回和不良影響
  • 市場機會
    • 支持佐劑研究的發展和產品發布的合作努力
  • 未來的趨勢
    • 技術進步
  • 促進因素和限制的影響：

第 6 章：疫苗佐劑市場 - 全球市場分析

  • 疫苗佐劑市場收入，2022-2030
    • 概述
  • 疫苗佐劑市場 - 收入和 2030 年預測

第 7 章：疫苗佐劑市場分析 - 依佐劑類別

  • 概述
  • 礦物鹽佐劑
  • 乳化助劑
  • 脂質體佐劑
  • 其他

第 8 章：疫苗佐劑市場分析 - 按類型

  • 人類疫苗佐劑
  • 獸用疫苗佐劑

第 9 章：疫苗佐劑市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 10 章：產業格局

  • 概述
  • 全球疫苗佐劑市場的成長策略
  • 有機發展
    • 概述
  • 無機發展
    • 概述

第 11 章：公司簡介

  • SPI Pharma Inc
  • GSK Plc
  • CSL Ltd
  • Seppic SA
  • Hawaii Biotech Inc
  • Dynavax Technologies Corp
  • InvivoGen SAS
  • Croda International Plc
  • Novavax Inc
  • Phibro Animal Health Corp

第 12 章：附錄

Product Code: TIPRE00004430

The vaccine adjuvants market is expected to grow from US$ 2.482 billion in 2022 to US$ 6.931 billion by 2028; it is expected to grow at a CAGR of 13.7% from 2022 to 2028. Support for developments in adjuvant studies and collaborative efforts for product launches creates opportunities for the vaccine adjuvant market, a standalone factor responsible for influential market growth driving the vaccine adjuvants market growth.

An adjuvant is a component added to vaccine preparations to create a stronger immune response in people receiving the vaccine. The rising occurrence of infectious disease outbreaks and pandemics and regulatory approvals of veterinary vaccine adjuvants are the key factors propelling the market development. However, product recall and adverse effects hamper the vaccine adjuvant market growth.

Growth Drivers:

Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches Creates Opportunities for Vaccine Adjuvant Market

The National Institute of Allergy and Infectious Disease (NIAID) plays an important role in developing, discovering, and characterizing new vaccine adjuvants. The institute plays a crucial role in improving the efficacy of current vaccines, designing new or better vaccines against existing and emerging infectious diseases, and developing vaccines to treat allergies, autoimmune diseases, and cancer. Additionally, NIAID's vaccine adjuvant research program aims to develop a set of adjuvants, including candidates that can be matched with antigens to optimize the final vaccine efficacy. Therefore, to foster the collaboration between NIAID-supported vaccine adjuvant researchers and a broader scientific community, NIAID established the Vaccine Adjuvant Compendium (VAC) in 2020. This web-based tool displays adjuvant characteristics to help vaccine developers identify adjuvants suitable for their target disease.

Companies in the vaccine business, such as SK Biosciences and GSK, are producing adjuvants on a large scale to meet global demand by implementing growth strategies such as collaborations. For instance, in April 2022, SK Biosciences and GSK announced the submission of a biological license application for SKYCovione to the Korean Ministry of Food and Drug Safety (KMFDS) following positive data obtained in Phase 3 clinical trials. Therefore, the support provided by various government authorities to foster vaccine adjuvant research and development, collaborations between top manufacturers, and innovative product launches through such collaborative business strategies are likely to provide lucrative opportunities for the growth of the vaccine adjuvants market during the forecast period.

The mineral salt adjuvant segment held the largest share of the vaccine adjuvant market by adjuvant class 2022. The market for the emulsion adjuvant segment is anticipated to grow at the fastest CAGR of 14.6% during the forecast period. Mineral salts such as insoluble aluminum salts and calcium phosphates are used as adjuvants in vaccine formulations. Aluminum salt-based adjuvants help induce early and long-lasting protective immunity. Aluminum adjuvants indicated for use in human vaccines are regulated by the US Food and Drug Administration (FDA), and small amounts of aluminum are added to help the body build higher immunogenicity than the antigen alone in the vaccine. Mineral salt adjuvant formulation at the inflammatory site produces a fast immune response by releasing pro-inflammatory cytokines. Therefore, the ability of mineral salt-based adjuvants to induce a fast immune response toward antigens favors the vaccine adjuvants market growth.

In 2022, North America contributed the largest global vaccine adjuvant market share. Asia Pacific is expected to register the highest CAGR during 2022-2030. Accelerated product approvals for vaccine adjuvants bolster market growth in North America. Additionally, the presence of top manufacturers producing adjuvants further enhances the overall market growth.

Fast product approval processes benefit the vaccine adjuvants market in the US. In May 2023, GlaxoSmithKline (GSK) won US Food and Drug Administration (FDA) approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) vaccine intended for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV). Thus, Arexvy became the world's first FDA-approved RSV vaccine for older adults. In October 2022, Novavax, Inc. received an Emergency Use Authorization (EUA) from the FDA for its COVID-19 adjuvanted vaccine, indicated as a booster for adult patients.

Industry Developments and Future Opportunities:

Various strategic developments by leading players operating in the vaccine adjuvant market are listed below:

In April 2022, GSK plc and SK Bioscience submitted a biologics license application for SKYCovione, a recombinant protein-based, adjuvanted COVID-19 vaccine candidate. It contains GSK's pandemic adjuvant. The companies have submitted a biologics license application to the Korean Ministry of Food and Drug Safety following the positive data obtained in Phase III clinical trials.

In November 2021, Seppic launched MONTANIDE GEL P PR, an aqueous adjuvant based on a polymeric technology exclusively dedicated to avian injectable vaccines, meeting the need for innocuity in the avian market. In addition, MONTANIDE GEL P PR is particularly stable and can resist destabilizing antigenic media frequently used in avian vaccines.

In October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in expanding Q-Vant's proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.

In January 2023, the Korean Ministry of Food and Drug Safety (KMFDS) granted SK Bioscience enhanced manufacturing and marketing authorization for NuvaxovidTM to be administered to adults aged 18 and above as a booster.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the vaccine adjuvants market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global vaccine adjuvants market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Vaccine Adjuvants Market Landscape

  • 4.1 PEST Analysis

5. Vaccine Adjuvants Market - Key Market Dynamics

  • 5.1 Vaccine Adjuvants Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Number of Infectious Disease Outbreaks and Pandemic
    • 5.2.2 Approvals of Veterinary Vaccine Adjuvants
  • 5.3 Market Restraints
    • 5.3.1 Product Recalls and Adverse Effects
  • 5.4 Market Opportunity
    • 5.4.1 Support for Developments in Adjuvant Studies and Collaborative Efforts for Product Launches
  • 5.5 Future Trends
    • 5.5.1 Technological Advancements
  • 5.6 Impact of Drivers and Restraints:

6. Vaccine Adjuvants Market - Global Market Analysis

  • 6.1 Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
    • 6.1.1 Overview
  • 6.2 Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Vaccine Adjuvants Market Analysis - by Adjuvant Class

  • 7.1 Overview
  • 7.2 Mineral Salt Adjuvant
    • 7.2.1 Overview
    • 7.2.2 Mineral Salt Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Emulsion Adjuvant
    • 7.3.1 Overview
    • 7.3.2 Emulsion Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Liposome Adjuvant
    • 7.4.1 Overview
    • 7.4.2 Liposome Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Others
    • 7.5.1 Overview
    • 7.5.2 Others: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Vaccine Adjuvants Market Analysis - by Type

  • 8.1 Human Vaccine Adjuvant
    • 8.1.1 Overview
    • 8.1.2 Human Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.2 Veterinary Vaccine Adjuvant
    • 8.2.1 Overview
    • 8.2.2 Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Vaccine Adjuvants Market - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Vaccine Adjuvants Market Overview
    • 9.1.2 North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
      • 9.1.2.1 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.1.2.2 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.1.3 North America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.1.3.1 United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.1.1 Overview
        • 9.1.3.1.2 United States: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.1.3 United States: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.1.4 United States: Vaccine Adjuvants Market Breakdown, by Type
      • 9.1.3.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.2.1 Overview
        • 9.1.3.2.2 Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.2.3 Canada: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.2.4 Canada: Vaccine Adjuvants Market Breakdown, by Type
      • 9.1.3.3 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.3.1 Overview
        • 9.1.3.3.2 Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.1.3.3.3 Mexico: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.1.3.3.4 Mexico: Vaccine Adjuvants Market Breakdown, by Type
  • 9.2 Europe
    • 9.2.1 Europe Vaccine Adjuvants Market Overview
    • 9.2.2 Europe: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
      • 9.2.2.1 Europe: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.2.2.2 Europe: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.2.3 Europe: Vaccine Adjuvants Market
      • 9.2.3.1 Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.1.1 Overview
        • 9.2.3.1.2 Germany: Glucose Monitoring Devices Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.1.3 Germany: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.1.4 Germany: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.2.1 Overview
        • 9.2.3.2.2 United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.2.3 United Kingdom: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.2.4 United Kingdom: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.3 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.3.1 Overview
        • 9.2.3.3.2 France: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.3.3 France: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.3.4 France: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.4 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.4.1 Overview
        • 9.2.3.4.2 Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.4.3 Italy: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.4.4 Italy: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.5 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.5.1 Overview
        • 9.2.3.5.2 Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.5.3 Spain: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.5.4 Spain: Vaccine Adjuvants Market Breakdown, by Type
      • 9.2.3.6 Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.6.1 Overview
        • 9.2.3.6.2 Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.2.3.6.3 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.2.3.6.4 Rest of Europe: Vaccine Adjuvants Market Breakdown, by Type
  • 9.3 Asia Pacific
    • 9.3.1 Asia Pacific Vaccine Adjuvants Market Overview
    • 9.3.2 Asia Pacific: Vaccine Adjuvants Market
      • 9.3.2.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
    • 9.3.3 Asia Pacific: Vaccine Adjuvants Market
      • 9.3.3.1 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.3.4 Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.3.4.1 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.1.1 Overview
        • 9.3.4.1.2 China: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.1.3 China: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.1.4 China: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.2.1 Overview
        • 9.3.4.2.2 Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.2.3 Japan: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.2.4 Japan: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.3 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.3.1 Overview
        • 9.3.4.3.2 India: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.3.3 India: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.3.4 India: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.4 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.4.1 Overview
        • 9.3.4.4.2 Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.4.3 Australia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.4.4 Australia: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.5 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.5.1 Overview
        • 9.3.4.5.2 South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.5.3 South Korea: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.5.4 South Korea: Vaccine Adjuvants Market Breakdown, by Type
      • 9.3.4.6 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.6.1 Overview
        • 9.3.4.6.2 Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.3.4.6.3 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.3.4.6.4 Rest of APAC: Vaccine Adjuvants Market Breakdown, by Type
  • 9.4 Middle East and Africa
    • 9.4.1 Middle East and Africa Vaccine Adjuvants Market Overview
    • 9.4.2 Middle East and Africa: Vaccine Adjuvants Market
      • 9.4.2.1 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
      • 9.4.2.2 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.4.3 Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.4.3.1 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.1.1 Overview
        • 9.4.3.1.2 Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.1.3 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.1.4 Saudi Arabia: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.2.1 Overview
        • 9.4.3.2.2 South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.2.3 South Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.2.4 South Africa: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.3 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.3.1 Overview
        • 9.4.3.3.2 United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.3.3 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.3.4 United Arab Emirates: Vaccine Adjuvants Market Breakdown, by Type
      • 9.4.3.4 Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.4.1 Overview
        • 9.4.3.4.2 Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.4.3.4.3 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.4.3.4.4 Rest of Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Type
  • 9.5 South and Central America
    • 9.5.1 South and Central America Vaccine Adjuvants Market Overview
    • 9.5.2 South and Central America: Vaccine Adjuvants Market
      • 9.5.2.1 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Adjuvant Class
    • 9.5.3 South and Central America: Vaccine Adjuvants Market
      • 9.5.3.1 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Type
    • 9.5.4 South and Central America: Vaccine Adjuvants Market - Revenue and Forecast Analysis - by Country
      • 9.5.4.1 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.1.1 Overview
        • 9.5.4.1.2 Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.1.3 Brazil: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.1.4 Brazil: Vaccine Adjuvants Market Breakdown, by Type
      • 9.5.4.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.2.1 Overview
        • 9.5.4.2.2 Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.2.3 Argentina: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.2.4 Argentina: Vaccine Adjuvants Market Breakdown, by Type
      • 9.5.4.3 Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.3.1 Overview
        • 9.5.4.3.2 Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
        • 9.5.4.3.3 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Adjuvant Class
        • 9.5.4.3.4 Rest of South and Central America: Vaccine Adjuvants Market Breakdown, by Type

10. Industry Landscape

  • 10.1 Overview
  • 10.2 Growth Strategies in the Global Vaccine Adjuvants Market
  • 10.3 Organic Developments
    • 10.3.1 Overview
  • 10.4 Inorganic Developments
    • 10.4.1 Overview

11. Company Profiles

  • 11.1 SPI Pharma Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 GSK Plc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 THREATS
    • 11.2.7 Key Developments
  • 11.3 CSL Ltd
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Seppic SA
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Hawaii Biotech Inc
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Dynavax Technologies Corp
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 InvivoGen SAS
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 Croda International Plc
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Novavax Inc
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments
  • 11.10 Phibro Animal Health Corp
    • 11.10.1 Key Facts
    • 11.10.2 Business Description
    • 11.10.3 Products and Services
    • 11.10.4 Financial Overview
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.1 Glossary of Terms

List Of Tables

  • Table 1. Vaccine Adjuvants Market Segmentation
  • Table 2. North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 3. North America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 4. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 5. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 6. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 7. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 8. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 9. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 10. Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 11. Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 13. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 14. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 15. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 16. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 17. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 18. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 19. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 20. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 21. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 23. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 24. Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 25. Asia Pacific: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 26. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 27. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 28. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 29. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 30. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 31. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 33. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 34. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 35. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 36. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 37. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 38. Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 39. Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 40. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 41. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 42. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 43. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 44. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 45. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 46. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 47. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 48. South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 49. South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 50. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 51. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 52. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 53. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 54. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Adjuvant Class
  • Table 55. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 56. Organic Developments Done by Companies
  • Table 57. Inorganic Developments Done by Companies
  • Table 58. Glossary of Terms, Vaccine Adjuvants Market

List Of Figures

  • Figure 1. Vaccine Adjuvants Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Vaccine Adjuvants Market Revenue (US$ Million), 2022-2030
  • Figure 5. Vaccines Adjuvants Market, By Geography Forecast Analysis, 2022 & 2030
  • Figure 6. Vaccine Adjuvants Market Share (%) - by Adjuvant Class (2022 and 2030)
  • Figure 7. Mineral Salt Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Emulsion Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Liposome Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Others: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
  • Figure 12. Human Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Veterinary Vaccine Adjuvant: Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. North America: Vaccine Adjuvants Market by Key Countries - Revenue (2022) US$ Million
  • Figure 15. North America Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. North America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 17. United States: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 18. Canada: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 19. Mexico: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 20. Europe: Vaccine Adjuvants Market - Revenue by Key Countries Revenue 2022 (US$ Million)
  • Figure 21. Europe Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 22. Europe: Vaccine Adjuvants Market (2022 and 2030)
  • Figure 23. Germany: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 24. United Kingdom: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 25. France: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 26. Italy: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 27. Spain: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Rest of Europe: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. Asia Pacific: Vaccine Adjuvants Market - Revenue by Key Countries 2022 (US$ Million)
  • Figure 30. Asia Pacific: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. Asia Pacific: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 32. China: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Japan: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 34. India: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 35. Australia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 36. South Korea: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 37. Rest of APAC: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 38. Middle East and Africa: Vaccine Adjuvants Market by Key Countries - Revenue 2022 (US$ Million)
  • Figure 39. Middle East and Africa: Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)
  • Figure 40. Middle East and Africa: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 41. Saudi Arabia: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 42. South Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 43. United Arab Emirates: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 44. Rest of Middle East and Africa: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 45. South and Central America: Vaccine Adjuvants Market by Key Countries - Revenue 2022 (US$ Million)
  • Figure 46. South and Central America: Vaccine Adjuvants Market, Revenue and Forecast to 2030 (US$ Million)
  • Figure 47. South and Central America: Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 48. Brazil: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 49. Argentina: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 50. Rest of South and Central America: Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 51. Growth Strategies in the Global Vaccine Adjuvants Market